v3.25.4

Segment Information (Tables)

6 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

Summary of Financial Data for Development of Pharmaceutical Products Segments

The following tables summarize our financial data for our segments (in thousands):

		For the Three Months Ended December 31, 2025
		Digital Asset Treasury Strategy				Development of Pharmaceutical Products				Total Segment Costs				Corporate Expenses				Consolidated
Operating and other (income) expense
Employee expenses		$	144			$	23			$	167			$	332			$	499
Other segment expenses(1)			13				—				13				838				851
Professional fees			371				—				371				357				728
Legal fees			5				172				177				383				560
voruciclib			—				23				23				—				23
Asset management fee and advisory fees			690				—				690				—				690
Change in fair value of digital assets			26,516				—				26,516				—				26,516
Change in fair value of digital assets     receivable, net			1,533				—				1,533				—				1,533
Gain on derivative liabilities			(541	)			—				(541	)			—				(541	)
Interest and dividend income(2)			—				—				—				(60	)			(60	)
Total operating and other (income)       expense			28,731				218				28,949				1,850				30,799
Total segment costs loss and net loss		$	(28,731	)		$	(218	)		$	(28,949	)		$	(1,850	)		$	(30,799	)

___________

(1) Includes product development costs associated with zandelisib determined to be immaterial for both periods presented, occupancy costs, share-based compensation costs, administrative costs, travel and business taxes.

(2) Interest and dividend income are solely attributable to our cash and cash equivalents.

		For the Three Months Ended December 31, 2024
		Development of Pharmaceutical Products and Total Segment Costs				Corporate Expenses				Consolidated
Operating and other (income) expense
Employee expenses		$	401			$	1,675			$	2,076
Other segment expenses(1)			(79	)			468				389
Professional fees			9				288				297
Legal fees			212				505				717
voruciclib			81				—				81
ME-344			(104	)			—				(104	)
Gain on disposition of nonfinancial asset			—				(500	)			(500	)
Interest and dividend income(2)			—				(279	)			(279	)
Total operating and other (income)       expense			520				2,157				2,677
Total segment costs loss and net loss		$	(520	)		$	(2,157	)		$	(2,677	)

___________

(1) Includes product development costs associated with zandelisib determined to be immaterial for both periods presented, occupancy costs (including rent and utilities), share-based compensation costs, depreciation expense, administrative costs, travel and business taxes.

(2) Interest and dividend income are solely attributable to our cash and cash equivalents.

		For the Six Months Ended December 31, 2025
		Digital Asset Treasury Strategy				Development of Pharmaceutical Products				Total Segment Costs				Corporate Expenses				Consolidated
Operating and other (income) expense
Employee expenses		$	376			$	23			$	399			$	679			$	1,078
Other segment expenses(1)			33				5				38				1,649				1,687
Professional fees			441				2				443				1,056				1,499
Legal fees			112				366				478				528				1,006
voruciclib			—				26				26				—				26
Asset management fee and advisory fees			1,163				—				1,163				—				1,163
Change in fair value of digital assets			27,147				—				27,147				—				27,147
Change in fair value of digital assets     receivable, net			1,533				—				1,533				—				1,533
Gain on derivative liabilities			(541	)			—				(541	)			—				(541	)
Interest and dividend income(2)			—				—				—				(160	)			(160	)
Total operating and other (income)       expense			30,264				422				30,686				3,752				34,438
Total segment costs loss and net loss		$	(30,264	)		$	(422	)		$	(30,686	)		$	(3,752	)		$	(34,438	)

________

(1) Includes product development costs associated with zandelisib determined to be immaterial for both periods presented, occupancy costs, share-based compensation costs, administrative costs, travel and business taxes.

(2) Interest and dividend income are solely attributable to our cash and cash equivalents.

		For the Six Months Ended December 31, 2024
		Development of Pharmaceutical Products and Total Segment Costs				Corporate Expenses				Consolidated
Operating and other (income) expense
Employee expenses		$	2,366			$	4,633			$	6,999
Other segment expenses(1)			33				1,638				1,671
Professional fees			21				890				911
Legal fees			409				777				1,186
voruciclib			798				—				798
ME-344			253				—				253
Gain on disposition of nonfinancial asset			—				(500	)			(500	)
Interest and dividend income(2)			—				(634	)			(634	)
Total operating and other (income)       expense			3,880				6,804				10,684
Total segment costs loss and net loss		$	(3,880	)		$	(6,804	)		$	(10,684	)

________

(1) Includes product development costs associated with zandelisib determined to be immaterial for both periods presented, occupancy costs (including rent and utilities), share-based compensation costs, depreciation expense, administrative costs, travel and business taxes.

(2) Interest and dividend income are solely attributable to our cash and cash equivalents.

		December 31, 2025
		Digital Asset Treasury Strategy				Development of Pharmaceutical Products				Total Segment Assets				Corporate Assets				Consolidated
Current assets:
Cash and cash equivalent		$	—			$	—			$	—			$	8,758			$	8,758
Prepaid expenses and other current assets			1,061				51				1,112				1,042				2,154
Total current assets			1,061				51				1,112				9,800				10,912
Digital assets			63,970				—				63,970				—				63,970
Digital assets receivable, net			7,350				—				7,350				—				7,350
Other long-term assets			—				—				—				705				705
Total assets		$	72,381			$	51			$	72,432			$	10,505			$	82,937

		June 30, 2025
		Development of Pharmaceutical Products and Total Segment Assets				Corporate Assets				Consolidated
Current assets:
Cash and cash equivalent		$	—			$	18,011			$	18,011
Prepaid expenses and other current assets			25				249				274
Total current assets			25				18,260				18,285
Total assets		$	25			$	18,260			$	18,285

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration